Complete remission of OC-resistant catamenial shoulder joint pain and inguinal pain associated with extraperitoneal endometriosis following personalized GnRH agonist therapy.

Patients with severe extraperitoneal endometriosis require rapid remission and cannot wait for the effects of oral contraceptive hormones (OCs) to appear.
We successfully achieved personalized gonadotropin-releasing hormone agonist (GnRHa) therapy for a patient with catamenial right shoulder joint pain and right inguinal pain associated with extraperitoneal endometriosis, which was completely unable to be suppressed by OCs. A total of 15 subcutaneous GnRHa depot injections over a period of 19 months was performed according to the serum estradiol and LH levels, in order to maintain long-term amenorrhea without any estrogen-deprivation effects. No recurrence of the catamenial symptoms has been observed for more than 35 months after the final GnRHa depot injection.
Personalized GnRHa therapy should become the first-choice therapy for OC-resistant inoperable extraperitoneal endometriosis.
AuthorsT Tanaka, N Umesaki
JournalClinical and experimental obstetrics & gynecology (Clin Exp Obstet Gynecol) Vol. 36 Issue 1 Pg. 46-8 ( 2009) ISSN: 0390-6663 [Print] Italy
PMID19400418 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Fertility Agents, Female
  • Gonadotropin-Releasing Hormone
  • Leuprolide
  • Endometriosis (complications, drug therapy, pathology)
  • Female
  • Fertility Agents, Female (administration & dosage)
  • Gonadotropin-Releasing Hormone (agonists)
  • Humans
  • Inguinal Canal (pathology)
  • Injections, Subcutaneous
  • Leuprolide (administration & dosage)
  • Middle Aged
  • Shoulder Pain (drug therapy, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: